The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treat to Target: Rheumatoid Arthritis in Pregnant Patients

Treat to Target: Rheumatoid Arthritis in Pregnant Patients

October 1, 2012 • By Eliza F. Chakravarty, MD, MS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Treat to target” has become one of the most important buzz phrases in rheumatology today, particularly for rheumatoid arthritis (RA). The treat-to-target movement was based, at least in part, on data supporting tight control of other chronic diseases such as diabetes mellitus (DM) and hypertension (HTN) on improved long-term outcomes with reduction in end-organ damage. Indeed, one of the 10 recommendations for treat to target states, “The desired treatment target should be maintained throughout the remaining course of the disease.”1 Unfortunately, this goal does not always seem to apply to a growing population of RA patients—women who are or desire to become pregnant. It is precisely because of the introduction of successful treatment options for RA and the growing potential for remission that many women of childbearing age now feel healthy enough to consider childbearing and childrearing. However, there remains a reluctance to control disease activity during pregnancy for fear of adverse effects of drug exposure on the fetus. It is likely that, as rheumatologists trained in the prebiologic era, we have had relatively little experience with treating pregnant women in the past, and therefore have some discomfort with this topic.

You Might Also Like
  • Treat Rheumatoid Arthritis to Target
  • Patient’s Journey with Rheumatoid Arthritis Redefines ‘Treat to Target’
  • From the Expert: New Insights into Treating Pregnant Patients with Rheumatic Disease
Explore This Issue
October 2012

What the Current Data Show

For many decades, data on RA disease activity during pregnancy supported the notion that the great majority of patients experienced improvement or even remission of active disease during pregnancy, with improvements noted early in gestation and continuing through delivery.2 There was little corresponding study of the effects of RA upon pregnancy outcome. However, more recent data have cast some doubt on the magnitude of disease quiescence during pregnancy and the notion that fetal outcomes are unrelated to maternal disease activity. Prospective observational studies performed within the last decade using standardized measures of disease activities have begun to quantify the extent of disease burden during pregnancy. These have shown, in general, that there continues to be a good proportion of RA patients who experience improvements in disease activity during pregnancy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, in contrast to earlier reports, these data demonstrate that fewer than half of patients with moderate disease at conception experience a moderate or good response according to European League Against Rheumatism criteria by the third trimester, leaving the remaining women with a Disease Assessment Score–28 of >3.2 (intermediate and severe disease activity) during pregnancy.3 In the nonpregnant patient, this would be considered a failure. One could argue that pregnancy is an exception to the treat-to-target goals for two reasons: 1) this is a short period of time in a woman’s lifetime of RA; and 2) past data suggested no adverse pregnancy outcomes, therefore the risks of active disease to the fetus are too low to consider potential teratogenic risk of medication exposure.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biologics, drug, Methotrexate, patient care, pregnancy, Rheumatoid arthritisIssue: October 2012

You Might Also Like:
  • Treat Rheumatoid Arthritis to Target
  • Patient’s Journey with Rheumatoid Arthritis Redefines ‘Treat to Target’
  • From the Expert: New Insights into Treating Pregnant Patients with Rheumatic Disease
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.